Literature DB >> 22781393

The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.

Hui Ren1, Mingwei Chen, Ping Yue, Hui Tao, Taofeek K Owonikoko, Suresh S Ramalingam, Fadlo R Khuri, Shi-Yong Sun.   

Abstract

This study focuses on determining whether the combination of NYP-BKM120 (BKM120) and RAD001 exerts enhanced therapeutic effect against lung cancer. The combination of BKM120 and RAD001 exerted synergistic inhibitory effects on the growth of lung cancer cells both in culture and in mouse xenograft model. This combination abrogated RAD001-induced Akt phosphorylation and exerted enhanced suppressive effect on 4EBP1 phosphorylation. Collectively, we suggest that the combination of RAD001 and BKM120 may be an effective regimen for treatment of lung cancer, hence warranting further evaluation of the combination in the clinic.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22781393      PMCID： PMC3433638          DOI： 10.1016/j.canlet.2012.06.018

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  26 in total

Review 1.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

Review 2.  Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.

Authors:  Yulong L Chen; Ping-Y Law; Horace H Loh
Journal:  Curr Med Chem Anticancer Agents       Date:  2005-11

3.  Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.

Authors:  Yuhuan Zheng; Jing Yang; Jianfei Qian; Liang Zhang; Yong Lu; Haiyan Li; Heather Lin; Yongsheng Lan; Zhiqiang Liu; Jin He; Sungyoul Hong; Sheeba Thomas; Jatin Shah; Veera Baladandayuthapani; Larry W Kwak; Qing Yi
Journal:  J Mol Med (Berl)       Date:  2011-12-30       Impact factor: 4.599

4.  Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells.

Authors:  S Y Sun; P Yue; G S Wu; W S El-Deiry; B Shroot; W K Hong; R Lotan
Journal:  Oncogene       Date:  1999-04-08       Impact factor: 9.867

5.  Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells.

Authors:  S Y Sun; P Yue; M I Dawson; B Shroot; S Michel; W W Lamph; R A Heyman; M Teng; R A Chandraratna; K Shudo; W K Hong; R Lotan
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

6.  Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

Authors:  Xiangguo Liu; Ping Yue; Zhongmei Zhou; Fadlo R Khuri; Shi-Yong Sun
Journal:  J Natl Cancer Inst       Date:  2004-12-01       Impact factor: 13.506

7.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Authors:  Shi-Yong Sun; Laura M Rosenberg; Xuerong Wang; Zhongmei Zhou; Ping Yue; Haian Fu; Fadlo R Khuri
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

8.  The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.

Authors:  Shi-Yong Sun; Zhongmei Zhou; Ruoxiang Wang; Haian Fu; Fadlo R Khuri
Journal:  Cancer Biol Ther       Date:  2004-11-12       Impact factor: 4.742

Review 9.  The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.

Authors:  Robert T Abraham; James J Gibbons
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

10.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

Authors:  Kathryn E O'Reilly; Fredi Rojo; Qing-Bai She; David Solit; Gordon B Mills; Debra Smith; Heidi Lane; Francesco Hofmann; Daniel J Hicklin; Dale L Ludwig; Jose Baselga; Neal Rosen
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701
View more
  29 in total

1.  Cables1 complex couples survival signaling to the cell death machinery.

Authors:  Zhi Shi; Hae Ryon Park; Yuhong Du; Zijian Li; Kejun Cheng; Shi-Yong Sun; Zenggang Li; Haian Fu; Fadlo R Khuri
Journal:  Cancer Res       Date:  2014-10-31       Impact factor: 12.701

Review 2.  Targeted therapies in urothelial carcinoma.

Authors:  Monalisa Ghosh; Sam J Brancato; Piyush K Agarwal; Andrea B Apolo
Journal:  Curr Opin Oncol       Date:  2014-05       Impact factor: 3.645

3.  Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.

Authors:  Weilong Yao; Ping Yue; Guojing Zhang; Taofeek K Owonikoko; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Lett       Date:  2015-04-29       Impact factor: 8.679

4.  ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.

Authors:  M R Yun; H M Choi; H N Kang; Yw Lee; H-S Joo; D H Kim; H R Kim; M H Hong; S O Yoon; B C Cho
Journal:  Oncogene       Date:  2017-09-25       Impact factor: 9.867

5.  Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.

Authors:  Esther P Jane; Daniel R Premkumar; Alejandro Morales; Kimberly A Foster; Ian F Pollack
Journal:  J Pharmacol Exp Ther       Date:  2014-04-16       Impact factor: 4.030

6.  Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.

Authors:  L M Neri; A Cani; A M Martelli; C Simioni; C Junghanss; G Tabellini; F Ricci; P L Tazzari; P Pagliaro; J A McCubrey; S Capitani
Journal:  Leukemia       Date:  2013-07-29       Impact factor: 11.528

Review 7.  Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.

Authors:  Mark E Welker; George Kulik
Journal:  Bioorg Med Chem       Date:  2013-05-09       Impact factor: 3.641

Review 8.  Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer.

Authors:  Stavros Gkolfinopoulos; Giannis Mountzios
Journal:  Ann Transl Med       Date:  2018-04

9.  Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.

Authors:  Guoqing Qian; Jianping Guo; Karin A Vallega; Changjiang Hu; Zhen Chen; Yunfu Deng; Qiming Wang; Songqing Fan; Suresh S Ramalingam; Taofeek K Owonikoko; Wenyi Wei; Shi-Yong Sun
Journal:  Mol Cancer Res       Date:  2021-06-28       Impact factor: 5.852

10.  Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Authors:  Daniela Bressanin; Camilla Evangelisti; Francesca Ricci; Giovanna Tabellini; Francesca Chiarini; Pier Luigi Tazzari; Fraia Melchionda; Francesca Buontempo; Pasqualepaolo Pagliaro; Andrea Pession; James A McCubrey; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.